The immunotherapy drug Tecentriq (atezolizumab) was accepted earlier this 12 months by the U.S. Foodstuff and Drug Administration to deal with patients with newly diagnosed non-tiny mobile lung cancers (NSCLC), which comprise up to eighty five% of all lung tumors.
